mirvetuximab
immunogen
['nct04209855', 'mirasol']
during the 2023 annual meeting, key findings from the phase iii mirasol trial (nct04209855) were presented in an oral abstract session by . get more detailed insights and key finding from the trial: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry